|
|
Volumn 504, Issue 7479, 2013, Pages 198-
|
|
Diabetes drugs ride a bumpy road
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
CANAGLIFLOZIN;
DAPAGLIFLOZIN;
GLUCOSE;
INSULIN;
PROTEIN INHIBITOR;
ROSIGLITAZONE;
SODIUM GLUCOSE COTRANSPORTER 2;
SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;
UNCLASSIFIED DRUG;
BLADDER CANCER;
BREAST CANCER;
CARDIOVASCULAR DISEASE;
CEREBROVASCULAR ACCIDENT;
DIABETES MELLITUS;
DIABETIC OBESITY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
EPIDEMIC;
FOOD AND DRUG ADMINISTRATION;
GLUCOSE BLOOD LEVEL;
HEART FAILURE;
HUMAN;
INSULIN DEPENDENT DIABETES MELLITUS;
INSULIN SENSITIVITY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NOTE;
PRIORITY JOURNAL;
WEIGHT REDUCTION;
BLOOD GLUCOSE;
CLINICAL TRIALS AS TOPIC;
DIABETES MELLITUS;
GLUCOSIDES;
HEART DISEASES;
HUMANS;
HYPOGLYCEMIC AGENTS;
SODIUM-GLUCOSE TRANSPORTER 2;
WEIGHT LOSS;
|
|
EID: 84890358162
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/504198a Document Type: Note |
|
Times cited : (16)
|
|
References (0)
|
